Developer docs
API playgroundTry for free, no card

Search company profiles

Haplogen Gmbh

Full company profile

uuid0039jcc

Namestring
Haplogen Gmbh
Websiteurl
haplogen.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Haplogen GmbH is a privately held biotechnology firm headquartered in Vienna, Austria, founded in 2017. According to its firmographic profile, the company is organized around an innovative genetic technology platform, a description consistent with functional genomics and gene-discovery work — an area associated with the scientific founders Thijn Brummelkamp and Sebastian Nijman, both recognized for contributions to haploid genetic screening methodology. The firm operates with a very small team of 1-10 employees, indicating a research-focused or pre-commercial operating posture rather than a scaled commercial organization.

The company has no publicly disclosed products, services, pipeline assets, customers, partnerships, pricing, or funding rounds in the available source data, and its public website (haplogen.com) returned only a verification/loading page during data collection rather than substantive content. As a result, the underlying technology architecture, target indications, go-to-market strategy, and revenue mechanics cannot be characterized from the input. The business model is therefore not discernible: the firm may be operating as an internal R&D vehicle, a technology licensor, a platform-as-a-service provider to academic or industrial partners, or a dormant entity. This represents a material information gap for any investor diligence.

From a competitive positioning standpoint, the company's principal identifiable assets are its genetic technology platform claim and the scientific pedigree of its two founders, both of whom have published extensively in functional genomics. However, no patents, granted licenses, named collaborators, or commercial deals are disclosed, so defensibility and commercialization status remain unverifiable from the source material.

Short descriptiontext

Haplogen GmbH is a privately held Vienna-based biotechnology firm founded in 2017 around an innovative genetic technology platform, operated by a 1-10 person team and led by scientific founders Thijn Brummelkamp and Sebastian Nijman. No commercial products, customers, or revenue model are disclosed.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVienna, Austria
HQ citystring
Vienna
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biotechnology research, genetic technology platform, drug discovery services, functional genomics, biopharmaceutical research
Industry1 code
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology Research
No data
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Haplogen GmbH is a privately held biotechnology firm headquartered in Vienna, Austria, that operates on an innovative genetic technology platform. Founded in 2017 with 1–10 employees, the company applies genetic technologies to support biotechnology and pharmaceutical research activities.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Genetic Technology Platform
No data
Peers10 records
TypeEmerging player
Description

Single-cell multi-omics platform used in functional genomics and target validation workflows — adjacent enabling technology for next-generation genetic screens.

TypeBroad incumbent
Description

Established provider of functional genomics tools, cell line engineering, and screening services — overlapping target customer base and broader portfolio spanning CRISPR and haploid-genetics-derived reagents.

TypeEmerging player
Description

AI- and high-throughput biology-driven drug discovery platform; uses large-scale functional genomics and phenotypic screens at scale — adjacent approach with a much larger platform footprint.

TypeBroad incumbent
Description

Bioconvergence platform with cell-line and tissue-engineering tools relevant to functional genomics workflows — overlapping customer base of academic and pharma R&D groups.

TypeDirect peer
Description

Uses synthetic lethality and functional genomics to develop precision oncology therapeutics — overlapping methodology and target-discovery pipeline with a haploid-genetics-based platform.

TypeEmerging player
Description

Provider of pooled CRISPR and shRNA screening libraries and functional genomics services — comparable platform tooling used by pharma and academic labs for target discovery.

TypeBroad incumbent
Description

Largest life sciences tools provider, including reagents, instruments, and screening services used in functional genomics — broad incumbent serving the same end customers.

TypeDirect peer
Description

Synthetic lethality and genome-wide CRISPR screening platform for oncology target discovery — comparable scientific tooling and customer base (pharma partners) as Haplogen.

TypeDirect peer
Description

Functional genomics-driven drug discovery platform using CRISPR-enabled pooled screens to identify and validate novel therapeutic targets — direct overlap with Haplogen's target-discovery value proposition.

TypeDirect peer
Description

Also co-founded by Thijn Brummelkamp, Scenic Biotech applies haploid genetics and functional genomics to discover novel disease-modifying targets — closely mirroring Haplogen's scientific approach and platform thesis.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Haplogen Gmbh

Biotechnology Researchhaplogen.com

Haplogen GmbH is a privately held Vienna-based biotechnology firm founded in 2017 around an innovative genetic technology platform, operated by a 1-10 person team and led by scientific founders Thijn Brummelkamp and Sebastian Nijman. No commercial products, customers, or revenue model are disclosed.

What Haplogen Gmbh does

Haplogen GmbH is a privately held biotechnology firm headquartered in Vienna, Austria, founded in 2017. According to its firmographic profile, the company is organized around an innovative genetic technology platform, a description consistent with functional genomics and gene-discovery work — an area associated with the scientific founders Thijn Brummelkamp and Sebastian Nijman, both recognized for contributions to haploid genetic screening methodology. The firm operates with a very small team of 1-10 employees, indicating a research-focused or pre-commercial operating posture rather than a scaled commercial organization.

The company has no publicly disclosed products, services, pipeline assets, customers, partnerships, pricing, or funding rounds in the available source data, and its public website (haplogen.com) returned only a verification/loading page during data collection rather than substantive content. As a result, the underlying technology architecture, target indications, go-to-market strategy, and revenue mechanics cannot be characterized from the input. The business model is therefore not discernible: the firm may be operating as an internal R&D vehicle, a technology licensor, a platform-as-a-service provider to academic or industrial partners, or a dormant entity. This represents a material information gap for any investor diligence.

From a competitive positioning standpoint, the company's principal identifiable assets are its genetic technology platform claim and the scientific pedigree of its two founders, both of whom have published extensively in functional genomics. However, no patents, granted licenses, named collaborators, or commercial deals are disclosed, so defensibility and commercialization status remain unverifiable from the source material.

Haplogen Gmbh firmographics

Firmographics
Name
Haplogen Gmbh
Website
https://haplogen.com
Company type
Private
Founded year
2017
Headcount range
1–10 employees
Short description
Haplogen GmbH is a privately held Vienna-based biotechnology firm founded in 2017 around an innovative genetic technology platform, operated by a 1-10 person team and led by scientific founders Thijn Brummelkamp and Sebastian Nijman. No commercial products, customers, or revenue model are disclosed.
Ownership category
akta.pro rank

Haplogen Gmbh industry classification

Industry
Product category
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Biotechnology research
  • Genetic technology platform
  • Drug discovery services
  • Functional genomics
  • Biopharmaceutical research

Where Haplogen Gmbh is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
Austria
HQ region
Europe

Markets served

Haplogen Gmbh business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Haplogen Gmbh product offering

Product offering

Core offering

Haplogen GmbH is a privately held biotechnology firm headquartered in Vienna, Austria, that operates on an innovative genetic technology platform. Founded in 2017 with 1–10 employees, the company applies genetic technologies to support biotechnology and pharmaceutical research activities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genetic Technology Platform

Companies that use Haplogen Gmbh

Customer profile

Ideal customer profiles1 record

Haplogen Gmbh technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Haplogen Gmbh competitors and assessment

Company assessment

Emerging players

  • Mission Bio: Single-cell multi-omics platform used in functional genomics and target validation workflows — adjacent enabling technology for next-generation genetic screens.
  • Recursion Pharmaceuticals: AI- and high-throughput biology-driven drug discovery platform; uses large-scale functional genomics and phenotypic screens at scale — adjacent approach with a much larger platform footprint.
  • Cellecta: Provider of pooled CRISPR and shRNA screening libraries and functional genomics services — comparable platform tooling used by pharma and academic labs for target discovery.

Broad incumbents

  • Horizon Discovery (Revvity): Established provider of functional genomics tools, cell line engineering, and screening services — overlapping target customer base and broader portfolio spanning CRISPR and haploid-genetics-derived reagents.
  • BICO Group (CELLINK): Bioconvergence platform with cell-line and tissue-engineering tools relevant to functional genomics workflows — overlapping customer base of academic and pharma R&D groups.
  • Thermo Fisher Scientific: Largest life sciences tools provider, including reagents, instruments, and screening services used in functional genomics — broad incumbent serving the same end customers.

Direct peers

  • Tango Therapeutics: Uses synthetic lethality and functional genomics to develop precision oncology therapeutics — overlapping methodology and target-discovery pipeline with a haploid-genetics-based platform.
  • Repare Therapeutics: Synthetic lethality and genome-wide CRISPR screening platform for oncology target discovery — comparable scientific tooling and customer base (pharma partners) as Haplogen.
  • KSQ Therapeutics: Functional genomics-driven drug discovery platform using CRISPR-enabled pooled screens to identify and validate novel therapeutic targets — direct overlap with Haplogen's target-discovery value proposition.
  • Scenic Biotech: Also co-founded by Thijn Brummelkamp, Scenic Biotech applies haploid genetics and functional genomics to discover novel disease-modifying targets — closely mirroring Haplogen's scientific approach and platform thesis.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Haplogen Gmbh financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Haplogen Gmbh leadership team

Management profile

Number of profiles

Profiles2 records

Haplogen Gmbh funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Haplogen Gmbh M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haplogen Gmbh

What does Haplogen Gmbh do?

Haplogen GmbH is a privately held biotechnology firm headquartered in Vienna, Austria, that operates on an innovative genetic technology platform. Founded in 2017 with 1–10 employees, the company applies genetic technologies to support biotechnology and pharmaceutical research activities.

When was Haplogen Gmbh founded?

Haplogen Gmbh was founded in 2017. It employs 1 to 10 people.

Where is Haplogen Gmbh based?

Haplogen Gmbh is headquartered in Vienna, Austria, in the Europe region.

Who are Haplogen Gmbh's main competitors?

Emerging players on record are Mission Bio, Recursion Pharmaceuticals and Cellecta. Broad incumbents are Horizon Discovery (Revvity), BICO Group (CELLINK) and Thermo Fisher Scientific. Direct peers are Tango Therapeutics, Repare Therapeutics, KSQ Therapeutics and Scenic Biotech.

Does Haplogen Gmbh have an API?

No public API is recorded for Haplogen Gmbh.

What industry is Haplogen Gmbh in?

Haplogen Gmbh's product category is Biotechnology Research. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales